Venkatesh Preethi G K, Njei Basile, Sanaka Madhusudhan R, Navaneethan Udayakumar
Digestive Disease Institute, The Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA.
Int J Colorectal Dis. 2014 Aug;29(8):953-60. doi: 10.1007/s00384-014-1915-x. Epub 2014 Jun 10.
The impact of comorbidities on outcomes of patients with lower gastrointestinal bleeding (LGIB) remains unknown.
Investigate the prevalence of comorbidities and impact on outcomes of patients with LGIB.
The Nationwide Inpatient Sample 2010 was used to identify patients who had a primary discharge diagnosis of LGIB based on International Classification of Diseases, the 9th revision, clinical modification codes. The presence of comorbid illness was assessed using the Elixhauser index. Logistic regression models were used to assess the contributions of the individual Elixhauser comorbidities to predict in-hospital mortality.
A total of 58,296 discharges with LGIB were identified. The overall mortality was 2.3 %. Among the patients who underwent colonoscopy, 17.3 % of patients had therapeutic intervention. As the number of comorbidities increased (i.e., 0, 1, 2, or >3), mortality increased (1.7, 2.0, 2.4, and 2.4 %, respectively). The mortality rate was highest in patients >65 years of age (2.7 %). Patients >65 years of age with two or more comorbidities had a mortality rate of 5 % as compared to 2.6 % in those with less than two comorbidities. Congestive heart failure (odds ratio, 1.67 [95 % confidence interval, 1.48-1.95]), liver disease (2.64 [1.83-3.80]), renal failure (1.99 [1.70-2.33]), and weight loss (2.66 [2.27-3.12]) were associated with a significant increase in mortality rate. Comorbidities increased hospital stay and costs.
Comorbidities were associated with increased the risk of mortality and health care utilization in patients with LGIB. Identification of comorbidities and development of risk-adjustment tools may improve the outcome of patients with LGIB.
合并症对下消化道出血(LGIB)患者预后的影响尚不清楚。
调查合并症的患病率及其对LGIB患者预后的影响。
使用2010年全国住院患者样本,根据国际疾病分类第九版临床修订代码,确定以LGIB作为主要出院诊断的患者。使用埃利克斯豪泽指数评估合并症的存在情况。采用逻辑回归模型评估各埃利克斯豪泽合并症对预测住院死亡率的作用。
共识别出58296例LGIB出院病例。总体死亡率为2.3%。在接受结肠镜检查的患者中,17.3%的患者接受了治疗干预。随着合并症数量的增加(即0、1、2或>3种),死亡率上升(分别为1.7%、2.0%、2.4%和2.4%)。65岁以上患者的死亡率最高(2.7%)。65岁以上有两种或更多合并症的患者死亡率为5%,而合并症少于两种的患者死亡率为2.6%。充血性心力衰竭(比值比,1.67[95%置信区间,1.48 - 1.95])、肝病(2.64[1.83 - 3.80])、肾衰竭(1.99[1.70 - 2.33])和体重减轻(2.66[2.27 - 3.12])与死亡率显著增加相关。合并症增加了住院时间和费用。
合并症与LGIB患者死亡率增加及医疗资源利用增加相关。识别合并症并开发风险调整工具可能改善LGIB患者的预后。